RIGL250117C30000
- 1.40
- 0.000.00%
Rigel Pharmaceuticals Newsroom
Express News | Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dow Jumps Over 200 Points, Crude Oil Gains 1.5%
Rigel Pharmaceuticals Shares Are Trading Lower After B. Riley Securities Cut Its Price Target on the Stock From $27 to $20.
Express News | Rigel Pharmaceuticals Shares Are Trading Lower After B. Riley Securities Cut Its Price Target on the Stock From $27 to $20
Rigel Pharmaceuticals Price Target Raised to $25 From $15 at Cantor Fitzgerald
Rigel Pharmaceuticals Price Target Raised to $25.00/Share From $15.00 by Cantor Fitzgerald
Rigel Pharmaceuticals Is Maintained at Neutral by Cantor Fitzgerald
Is There An Opportunity With Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 40% Undervaluation?
Rigel Pharmaceuticals Reports Initial Efficacy, Safety Data From Cancer Drug Study
Rigel Pharmaceuticals Highlights Initial Data From Ongoing Phase 1b Study Evaluating R289 In LR-MDS At The 66th ASH Annual Meeting; R289 Was Generally Well Tolerated And Demonstrated Signs Of Preliminary Clinical Activity In Elderly Heavily Pretreated...
B.Riley Financial Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $27
B. Riley Adjusts Price Target on Rigel Pharmaceuticals to $27 From $17, Maintains Neutral Rating
AppLovin, MicroStrategy, and 28 Other Stocks That Could Be Bubbles
Rigel Pharmaceuticals Says Its R289 Hematology Drug Candidate Receives Fast-Track Designation From US FDA
Express News | Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk Mds
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
How Much Upside Is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28%
Rigel Pharmaceuticals Price Target Raised to $23 From $15 at Piper Sandler
Rigel Pharmaceuticals Analyst Ratings